Eli Lilly Announced Sunday At ESMO, Olomorasib Plus Chemoimmunotherapy Data Showing 62% Overall Response Rate, 14.5-Month Median Response Duration In First-Line KRAS G12C NSCLC
Share
Why It Matters
Eli Lilly showed that a new cancer medicine works well in early tests. When doctors see good early results like these, it can mean the medicine might help patients and the company later.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.